Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathologic characteristics and survival of male breast cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Backgrounds

Male breast cancer (MBC) is a rare disease and accounts for <1 % of all breast cancers.

Methods

We retrospectively analyzed clinicopathologic characteristics and prognosis of MBC patients who were diagnosed in our hospital between March 2002 and March 2012.

Results

The median age of diagnosis of MBC was 62 years, which was 9 years older than female breast cancer (FBC) patients. The highest proportion of MBC patients was in the 50–59-year age group. The percentage of invasive ductal carcinoma in MBC was much higher than in FBC (P = 0.000). The positive rate of estrogen receptors in MBC patients (87.9 %) was significantly higher than in FBC patients (P = 0.048), whereas HER-2 was positive in 17.2 % of MBC patients, which was significantly lower than in FBC patients (P = 0.001). There was a consistent significant difference in luminal subtypes of FBC and MBC patients (P = 0.000). The overall survival rates of MBC were significantly higher than FBC (P = 0.004). HER-2-positive patients had a statistically worse prognosis than HER-2-negative patients (P = 0.040). Lymph node metastasis and larger tumor size were also associated with poorer prognosis (P = 0.056 and P = 0.088). The level of hormones was examined in 7 patients, and abnormal hormone levels were detected in 4.

Conclusion

The FBC patients were significantly different from the MBC in clinicopathologic and prognostic characteristics. HER-2 positivity was an important factor for prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  2. Anonymous (2008) Cancer incidence in five continents, vol IX. IARC Sci Publ, pp 1–837

  3. Nirmul D, Pegoraro RJ, Jialal I et al (1983) The sex hormone profile of male patients with breast cancer. Br J Cancer 48:423–427

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Ballerini P, Recchione C, Cavalleri A et al (1990) Hormones in male breast cancer. Tumori 76:26–28

    PubMed  CAS  Google Scholar 

  5. Ravandi-Kashani F, Hayes TG (1998) Male breast cancer: a review of the literature. Eur J Cancer 34:1341–1347

    Article  PubMed  CAS  Google Scholar 

  6. Thorlacius S, Tryggvadottir L, Olafsdottir GH et al (1995) Linkage to BRCA2 region in hereditary male breast cancer. Lancet 346:544–545

    Article  PubMed  CAS  Google Scholar 

  7. Andre S, Pinto AE, Laranjeira C et al (2007) Male and female breast cancer—differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 74:323–327

    Article  PubMed  CAS  Google Scholar 

  8. Anderson WF, Jatoi I, Tse J et al (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:232–239

    Article  PubMed Central  PubMed  Google Scholar 

  9. Onami S, Ozaki M, Mortimer JE et al (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Kiluk JV, Lee MC, Park CK et al (2011) Male breast cancer: management and follow-up recommendations. Breast J 17:503–509

    Article  PubMed  Google Scholar 

  11. Ottini L, Palli D, Rizzo S et al (2010) Male breast cancer. Crit Rev Oncol Hematol 73:141–155

    Article  PubMed  Google Scholar 

  12. Tawil AN, Boulos FI, Chakhachiro ZI et al (2012) Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J 18:65–68

    Article  PubMed  Google Scholar 

  13. La Vecchia C, Levi F, Lucchini F (1992) Descriptive epidemiology of male breast cancer in Europe. Int J Cancer 51:62–66

    Article  PubMed  Google Scholar 

  14. Anonymous (2004) Male breast cancer rates rising. Health News 10:13

    Google Scholar 

  15. Ndom P, Um G, Bell EM et al (2012) A meta-analysis of male breast cancer in Africa. Breast 21(3):237–241

    Article  PubMed  Google Scholar 

  16. Tajima N, Tsukuma H, Oshima A (2001) Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol 11:1–7

    Article  PubMed  CAS  Google Scholar 

  17. Zhou FF, Xia LP, Guo GF et al (2010) Changes in therapeutic strategies in Chinese male patients with breast cancer: 40 years of experience in a single institute. Breast 19:450–455

    Article  PubMed  Google Scholar 

  18. Liu T, Tong Z, He L et al (2011) Clinicopathological characteristics and survival analysis of 87 male breast cancer cases. Breast Care (Basel) 6:446–451

    Article  PubMed Central  Google Scholar 

  19. Bourhafour M, Belbaraka R, Souadka A et al (2011) Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res Notes 4:219

    Article  PubMed Central  PubMed  Google Scholar 

  20. Giordano SH, Cohen DS, Buzdar AU et al (2004) Breast carcinoma in men: a population-based study. Cancer 101:51–57

    Article  PubMed  Google Scholar 

  21. Rudlowski C, Friedrichs N, Faridi A et al (2004) Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 84:215–223

    Article  PubMed  CAS  Google Scholar 

  22. Arslan UY, Oksuzoglu B, Ozdemir N et al (2012) Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol 29:554–560

    Google Scholar 

  23. Foerster R, Foerster FG, Wulff V et al (2011) Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer 11:335

    Article  PubMed Central  PubMed  Google Scholar 

  24. Dakin HK, Gray S, Barnes PJ et al (2007) Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 105:169–175

    Article  CAS  Google Scholar 

  25. Borgen PI, Wong GY, Vlamis V et al (1992) Current management of male breast cancer. A review of 104 cases. Ann Surg 215:451–457

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Anderson WF, Althuis MD, Brinton LA et al (2004) Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83:77–86

    Article  PubMed  Google Scholar 

  27. Giordano SH (2005) A review of the diagnosis and management of male breast cancer. Oncologist 10:471–479

    Article  PubMed  Google Scholar 

  28. Hill TD, Khamis HJ, Tyczynski JE et al (2005) Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 15:773–780

    Article  PubMed  Google Scholar 

  29. Pich A, Margaria E, Chiusa L et al (1999) Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 79:959–964

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  30. Fogh S, Hirsch AE, Langmead JP et al (2011) Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Clin Breast Cancer 11:39–45

    Article  PubMed  CAS  Google Scholar 

  31. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  32. Salvadori B, Saccozzi R, Manzari A et al (1994) Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 30A:930–935

    Article  PubMed  CAS  Google Scholar 

  33. Joshi MG, Lee AK, Loda M et al (1996) Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77:490–498

    Article  PubMed  CAS  Google Scholar 

  34. Erlichman C, Murphy KC, Elhakim T (1984) Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 2:903–909

    PubMed  CAS  Google Scholar 

  35. Thomas DB, Jimenez LM, McTiernan A et al (1992) Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol 135:734–748

    PubMed  CAS  Google Scholar 

  36. Misra SP, Misra V, Dwivedi M (1996) Cancer of the breast in a male cirrhotic: is there an association between the two? Am J Gastroenterol 91:380–382

    PubMed  CAS  Google Scholar 

  37. Calabresi E, De Giuli G, Becciolini A et al (1976) Plasma estrogens and androgens in male breast cancer. J Steroid Biochem 7:605–609

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Integrated Traditional and Western Medicine, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China

    Dongying Liu & Guangru Xie

  2. Department of Digestive Medicine, Tianjin Nankai Hospital, Tianjin, 300060, China

    Ming Chen

Authors
  1. Dongying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guangru Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Chen.

About this article

Cite this article

Liu, D., Xie, G. & Chen, M. Clinicopathologic characteristics and survival of male breast cancer. Int J Clin Oncol 19, 280–287 (2014). https://doi.org/10.1007/s10147-013-0555-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-013-0555-4

Keywords

Search

Navigation